Epizyme Inc (NASDAQ:EPZM) has received an average recommendation of “Buy” from the fourteen research firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $22.67.
A number of analysts have recently weighed in on the company. BidaskClub upgraded Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. ValuEngine lowered Epizyme from a “hold” rating to a “sell” rating in a research note on Monday, November 6th. Oppenheimer set a $26.00 target price on Epizyme and gave the company a “buy” rating in a research note on Tuesday, December 12th. Cann restated a “buy” rating and issued a $26.00 target price on shares of Epizyme in a research note on Thursday, November 2nd. Finally, Zacks Investment Research lowered Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total value of $246,600.00. Following the completion of the sale, the insider now directly owns 23,123 shares in the company, valued at $380,142.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 25.20% of the stock is owned by company insiders.
Shares of Epizyme (EPZM) opened at $15.25 on Friday. Epizyme has a 12 month low of $9.30 and a 12 month high of $20.45. The firm has a market capitalization of $1,060.00, a price-to-earnings ratio of -6.72 and a beta of 2.00.
Epizyme (NASDAQ:EPZM) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.02. equities research analysts forecast that Epizyme will post -2.23 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/20/epizyme-inc-epzm-given-consensus-rating-of-buy-by-brokerages.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.